Small-cap, Buy-rated Stocks With Positive Estimate Revision Factors - BofA

Seeking AlphaJun 26 02:07

Janux Therapeutics Insider Sold Shares Worth $82,125,000, According to a Recent SEC Filing

Jay Lichter, 10% Owner, Director, on June 03, 2024, sold 1,500,000 shares in Janux Therapeutics (JANX) for $82,125,000. Following the Form 4 filing with the SEC, Lichter has control over a total of 3,

MT NewswiresJun 6 15:12

Janux Therapeutics(JANX.US) Officer Sells US$45.04 Million in Common Stock

$Janux Therapeutics(JANX.US)$ Officer Reardon Tighe sold 822.72K shares of common stock on Jun 3, 2024 at an average price of $54.75 for a total value of $45.04 million.Source: Announcement What is st

Futu NewsJun 6 08:05

JonesTrading Maintains Janux Therapeutics(JANX.US) With Buy Rating, Maintains Target Price $70

JonesTrading analyst Soumit Roy maintains $Janux Therapeutics(JANX.US)$ with a buy rating, and maintains the target price at $70.According to TipRanks data, the analyst has a success rate of 26.0% and

Futu NewsJun 6 02:31

Express News | Amarin (AMRN), a constituent stock, fell by 17.91%. Other constituent stocks, Summit Therapeutics Plc., 23Andme Holding Co., and Janux Therapeutics, fell by 17.36%-11.75%. Humacyte also fell by 9.50%. Hutchmed (China) (HCM) rose by 6.49%, Twist Bioscience

BreakingsJun 5 05:33

Form 144 | Janux Therapeutics(JANX.US) Director Proposes to Sell 7.21 Million in Common Stocks

SEC FILLINGS DISCLOSED/ Jun 3, $Janux Therapeutics(JANX.US)$ Director Avalon BioVentures I, LP intends to sell 131.2K shares of its common stock on Jun 3, with a total market value of approximately $7

Futu NewsJun 4 07:07